



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GRA Ex-25

| | | | |
|---------------------------|--|-------|---------|
| Cat. No.: | HY-50675 | | |
| CAS No.: | 307983-31-9 | | |
| Molecular Formula: | C ₂₉ H ₃₆ F ₃ N ₃ O ₅ | | |
| Molecular Weight: | 563.61 | | |
| Target: | GCGR | | |
| Pathway: | GPCR/G Protein | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (56.78 mM)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent | | Mass | | |
|---------------------------|---------------|--|-----------|-----------|------------|
| | Concentration | | 1 mg | 5 mg | 10 mg |
| | 1 mM | | 1.7743 mL | 8.8714 mL | 17.7428 mL |
| | 5 mM | | 0.3549 mL | 1.7743 mL | 3.5486 mL |
| | 10 mM | | 0.1774 mL | 0.8871 mL | 1.7743 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GRA Ex-25 is an inhibitor of glucagon receptor, with IC₅₀ of 56 and 55 nM for rat and human glucagon receptors, respectively.

IC₅₀ & Target

IC₅₀: 56 nM (rat glucagon receptor), 55 nM (human glucagon receptor)^[2]

In Vitro

GRA Ex-25 binds a human glucagon receptor (h-GlucRbind) with K_i of 63 nM and a moderate glucagon induced adenylate cyclase inhibition (h-GlucRcyclase) with K_i of 254 nM under our assay conditions^[1]. GRA Ex-25 has similar affinity to the rat

and human glucagon receptors (IC_{50} =56 and 55 nM, respectively)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

GRA Ex-25 (3 mg/kg, i.v.) significantly reduces blood glucose caused by exogenous administration of glucagon in rat model. GRA Ex-25 is able to inhibit the rise in blood glucose levels elicited by exogenous administered glucagon, most likely because of the direct inhibition of glucagon stimulated hepatic glucose output^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[2]

Non-fasted male Sprague Dawley rats (200 g) are maintained in the anaesthetized state during the test by s.c. administration of a 1:1 mixture of Hypnorm (fentanyl, 0.05 mg/mL and fluanizone, 2.5 mg/mL) and Dormicum (Midazolam, 1.25 mg/mL). Acatheter is inserted in a jugular vein for administration of compounds. Approximately 60 min after initiation of anesthesia, test compounds (0, 1, 3, 10 and 30 mg/kg) and glucagon (3 µg/kg) are administered in 5 min intervals, respectively. Samples for determination of blood glucose concentrations are taken from the tail tip 25 and 5 min prior to administration of the compound to represent average basal values and again 10 min after administration of glucagon (time for peak response of glucagon). The results are expressed as delta values calculated as the value obtained 10 min after glucagon administration minus the average of the two basal values.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kurukulasuriya R, et al. Biaryl amide glucagon receptor antagonists. *Bioorg Med Chem Lett*. 2004 May 3;14(9):2047-50.

[2]. Kurukulasuriya R, et al. Biaryl amide glucagon receptor antagonists. *Bioorg Med Chem Lett*. 2004 May 3;14(9):2047-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA